FDA approves Anoro Ellipta

Share this article:

 

The U.S. Food and Drug Administration have approved GlaxoSmithKline's Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive pulmonary disease.

Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist that can be used once a day, the first to combine two long-acting bronchodilators into a single inhaler. It is expected to be available in the first quarter of 2014.

 “We believe Anoro Ellipta will be an important treatment option for appropriate patients with COPD. …  This approval is a significant achievement for GSK,” said Darrell Baker, SVP & Head, GSK Global Respiratory Franchise.

Testing for Anoro Ellipta included seven clinical studies with almost 6,000 patients with COPD. 

Share this article:
close

Next Article in Products

More in Products

Aviv REIT offers public stock

Aviv REIT announced the public offering of 8 million shares of common stock at a public offering price of $24.10 per share.

NCAL unveils 2014 Assisted Living Week logo

NCAL unveils 2014 Assisted Living Week logo

The National Center for Assisted Living is encouraging communities to use the 2014 "The Magic of Music" logo to celebrate National Assisted Living Week.

New healthcare educational catalog available

New healthcare educational catalog available

Nasco has released its 2014-2015 Health Care Educational Materials catalog, which focuses on training with versatile medical procedure simulators.